Body weight changes with β-blocker use:: Results from GEMINI
Body weight changes with β-blocker use:: Results from GEMINI
复制标题
DOI：
10.1016/j.amjmed.2006.10.017
复制
发表时间：
2007-07-01
影响因子：
5.9
通讯作者：
Bakris, George L.
中科院分区：
文献类型：
--
作者：
Messerli, Franz H.;Bell, David S. H.;Bakris, George L.
目的：2型糖尿病患者通常超重，这可能导致不良的心血管结局。β-受体阻滞剂可能促进体重增加或阻碍体重减轻，并且是高危患者的关注点。糖尿病中的糖基化作用的当前分析：卡维地洛-美托洛尔在高血压患者中的比较（GEMINI）试验评估了卡维地洛和酒石酸美托洛尔对2型糖尿病和高血压患者体重增加的影响。（n = 1106）评价5个月后体重的变化。卡维地洛和酒石酸美托洛尔的平均（+/- SE）基线体重分别为97.5（+/- 20.1）kg和96.6（+/- 20.1）kg。平均（+/- SE）体重较基线变化的治疗差异（c vs m）为-1.02（+/- 0.21）公斤（95%置信区间[CI]，-1.43至-0.60; P 30 kg/m2）和病态肥胖组（BMI > 40 kg/m2）分别为-0.90 kg（95% CI，-1.5至-0.3; P = .002）和-1.84 kg（95% CI，-2.9至-0.8; P = .001）。成对相关性分析显示，体重变化和HbA（1c），HOMA-IR，或血压的变化之间没有显着的关联。结论：酒石酸美托洛尔与卡维地洛相比，体重增加;体重增加是最明显的高血压和糖尿病谁不服用胰岛素治疗的受试者。(c)2007爱思唯尔公司All rights reserved.
PURPOSE: Patients with type 2 diabetes are commonly overweight, which can contribute to poor cardiovascular outcomes. beta-blockers may promote weight gain, or hamper weight loss, and are a concern in high-risk patients. The current analysis of the Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial evaluates the effects of carvedilol and metoprolol tartrate on weight gain in patients with type 2 diabetes and hypertension.METHODS: This prespecified secondary analysis of the GEMINI study (n = 1106) evaluated change in body weight after 5 months.RESULTS: Mean (+/- SE) baseline weights were 97.5 (+/- 20.1) kg for carvedilol and 96.6 (+/- 20.1) kg for metoprolol tartrate. Treatment difference ( c vs m) in mean (+/- SE) weight change from baseline was -1.02 (+/- 0.21) kg ( 95% confidence interval [CI], -1.43 to -0.60; P 30 kg/m(2)) and morbidly obese groups (BMI > 40 kg/m(2)) were -0.90 kg ( 95% CI, -1.5 to -0.3; P = .002) and -1.84 kg (95% CI, -2.9 to -0.8; P = .001), respectively. Pairwise correlation analyses revealed no significant associations between weight change and change in HbA(1c), HOMA-IR, or blood pressure.CONCLUSIONS: Metoprolol tartrate was associated with increased weight gain compared to carvedilol; weight gain was most pronounced in subjects with hypertension and diabetes who were not taking insulin therapy. (c) 2007 Elsevier Inc. All rights reserved.